Findings

What do systematic reviews say?

10 questions · 10 findings · 2 reviews · Metabolic and Endocrine Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 20%GRADE not reported 1 · 10%Very low 5 · 50%Low 2 · 20%Moderate 0 · 0%High 0 · 0%

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Serious adverse events (N) · people at increased risk for developing type 2 diabetes

The review found no eligible studies for this question.

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs insulin

Serious adverse events

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs meglitinides

Serious adverse events

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 112 participants
GRADE not reported

Metformin vs thiazolidinediones

SAEs

It is very uncertain whether summary of findings of metformin monotherapy for adults with type 2… changes serious adverse events (SAE) compared with thiazolidinediones (very low certainty).

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
RR 0.95 [0.84, 1.09]
4 studies · 3208 participants
Very low

Metformin vs dipeptidyl‐peptidase 4 inhibitors

SAEs

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1977 participants
Very low

Metformin vs glucagon like peptide‐1 analogues

SAEs

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 807 participants
Very low

Metformin vs sulphonylureas

SAEs

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 3081 participants
Very low

Summary of findings: pioglitazone monotherapy vs intensive behaviour‐changing intervention

Serious adverse events (N) · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 103 participants
Low

Summary of findings: pioglitazone monotherapy vs placebo

Serious adverse events (N) · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
3 [0.32, 28.22]
2 studies · 187 participants
Very low

Summary of findings: pioglitazone monotherapy vs no intervention

Serious adverse events (N) · people at increased risk for developing type 2 diabetes

Summary of findings: pioglitazone monotherapy showed no clear difference in serious adverse events (N) compared with no intervention (low certainty).

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
RR 0.71 [0.38, 1.32]
7 studies · 1211 participants
Low